Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER Open-Label Extension in Schizophrenia
NCT00668837Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2004
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Johnson & Johnson. Primary endpoint: Safety and Tolerability of Flexibly-dosed ER OROS Paliperidone at 52 weeks. Started Feb 2004; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00668837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668837.